These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

313 related articles for article (PubMed ID: 20087229)

  • 1. Are there imaging characteristics associated with epidermal growth factor receptor and KRAS mutations in patients with adenocarcinoma of the lung with bronchioloalveolar features?
    Glynn C; Zakowski MF; Ginsberg MS
    J Thorac Oncol; 2010 Mar; 5(3):344-8. PubMed ID: 20087229
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epidermal growth factor receptor mutation and pathologic-radiologic correlation between multiple lung nodules with ground-glass opacity differentiates multicentric origin from intrapulmonary spread.
    Chung JH; Choe G; Jheon S; Sung SW; Kim TJ; Lee KW; Lee JH; Lee CT
    J Thorac Oncol; 2009 Dec; 4(12):1490-5. PubMed ID: 19844187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Frequency of EGFR and KRAS mutations in Japanese patients with lung adenocarcinoma with features of the mucinous subtype of bronchioloalveolar carcinoma.
    Hata A; Katakami N; Fujita S; Kaji R; Imai Y; Takahashi Y; Nishimura T; Tomii K; Ishihara K
    J Thorac Oncol; 2010 Aug; 5(8):1197-200. PubMed ID: 20661086
    [TBL] [Abstract][Full Text] [Related]  

  • 4. EGFR L858R mutation is associated with lung adenocarcinoma patients with dominant ground-glass opacity.
    Yang Y; Yang Y; Zhou X; Song X; Liu M; He W; Wang H; Wu C; Fei K; Jiang G
    Lung Cancer; 2015 Mar; 87(3):272-7. PubMed ID: 25582278
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib.
    Miller VA; Riely GJ; Zakowski MF; Li AR; Patel JD; Heelan RT; Kris MG; Sandler AB; Carbone DP; Tsao A; Herbst RS; Heller G; Ladanyi M; Pao W; Johnson DH
    J Clin Oncol; 2008 Mar; 26(9):1472-8. PubMed ID: 18349398
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
    Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
    PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adenocarcinomas with predominant ground-glass opacity: correlation of morphology and molecular biomarkers.
    Aoki T; Hanamiya M; Uramoto H; Hisaoka M; Yamashita Y; Korogi Y
    Radiology; 2012 Aug; 264(2):590-6. PubMed ID: 22653188
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ground-glass opacity nodules: histopathology, imaging evaluation, and clinical implications.
    Lee HY; Lee KS
    J Thorac Imaging; 2011 May; 26(2):106-18. PubMed ID: 21508733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
    Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
    J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Epidermal growth factor receptor mutation in lung adenocarcinomas: relationship with CT characteristics and histologic subtypes.
    Lee HJ; Kim YT; Kang CH; Zhao B; Tan Y; Schwartz LH; Persigehl T; Jeon YK; Chung DH
    Radiology; 2013 Jul; 268(1):254-64. PubMed ID: 23468578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic implication of EGFR, KRAS, and TP53 gene mutations in a large cohort of Japanese patients with surgically treated lung adenocarcinoma.
    Kosaka T; Yatabe Y; Onozato R; Kuwano H; Mitsudomi T
    J Thorac Oncol; 2009 Jan; 4(1):22-9. PubMed ID: 19096302
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A brief retrospective report on the feasibility of epidermal growth factor receptor and KRAS mutation analysis in transesophageal ultrasound- and endobronchial ultrasound-guided fine needle cytological aspirates.
    Schuurbiers OC; Looijen-Salamon MG; Ligtenberg MJ; van der Heijden HF
    J Thorac Oncol; 2010 Oct; 5(10):1664-7. PubMed ID: 20871266
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epidermal growth factor receptor mutation status in stage I lung adenocarcinoma with different image patterns.
    Hsu KH; Chen KC; Yang TY; Yeh YC; Chou TY; Chen HY; Tsai CR; Chen CY; Hsu CP; Hsia JY; Chuang CY; Tsai YH; Chen KY; Huang MS; Su WC; Chen YM; Hsiung CA; Chang GC; Chen CJ; Yang PC
    J Thorac Oncol; 2011 Jun; 6(6):1066-72. PubMed ID: 21512404
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pulmonary pleomorphic carcinoma: a clinicopathological study including EGFR mutation analysis.
    Kaira K; Horie Y; Ayabe E; Murakami H; Takahashi T; Tsuya A; Nakamura Y; Naito T; Endo M; Kondo H; Nakajima T; Yamamoto N
    J Thorac Oncol; 2010 Apr; 5(4):460-5. PubMed ID: 20107421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutation of TP53 and alteration of p14(arf) expression in EGFR- and KRAS-mutated lung adenocarcinomas.
    Cortot AB; Younes M; Martel-Planche G; Guibert B; Isaac S; Souquet PJ; Commo F; Girard P; Fouret P; Brambilla E; Hainaut P; Soria JC
    Clin Lung Cancer; 2014 Mar; 15(2):124-30. PubMed ID: 24169260
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Relationship between EGFR and KRAS mutations and prognosis in Chinese patients with non-small cell lung cancer: a mutation analysis with real-time polymerase chain reaction using scorpion amplification refractory mutation system].
    Gao J; Chen JQ; Zhang L; Liang ZY
    Zhonghua Bing Li Xue Za Zhi; 2012 Oct; 41(10):652-6. PubMed ID: 23302304
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Epidermal growth factor receptor-related tumor markers and clinical outcomes with erlotinib in non-small cell lung cancer: an analysis of patients from german centers in the TRUST study.
    Schneider CP; Heigener D; Schott-von-Römer K; Gütz S; Laack E; Digel W; Guschall WR; Franke A; Bodenstein H; Schmidtgen C; Reck M
    J Thorac Oncol; 2008 Dec; 3(12):1446-53. PubMed ID: 19057271
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LKB1 mutations frequently detected in mucinous bronchioloalveolar carcinoma.
    Osoegawa A; Kometani T; Nosaki K; Ondo K; Hamatake M; Hirai F; Seto T; Sugio K; Ichinose Y
    Jpn J Clin Oncol; 2011 Sep; 41(9):1132-7. PubMed ID: 21816872
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Epidermal growth factor receptor gene mutation and computed tomographic findings in peripheral pulmonary adenocarcinoma.
    Yano M; Sasaki H; Kobayashi Y; Yukiue H; Haneda H; Suzuki E; Endo K; Kawano O; Hara M; Fujii Y
    J Thorac Oncol; 2006 Jun; 1(5):413-6. PubMed ID: 17409892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bronchioloalveolar carcinoma and adenocarcinoma with bronchioloalveolar features presenting as ground-glass opacities on CT.
    Mirtcheva RM; Vazquez M; Yankelevitz DF; Henschke CI
    Clin Imaging; 2002; 26(2):95-100. PubMed ID: 11852215
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.